The post-Facebook era has arrived at SecondMarket as the company issues its first private company market report since the Facebook IPO.
And the crowd goes wild! Time Warner scoops up all-things-sports-site Bleacher Report in a deal said to be worth quite a bundle.
Ares Capital Corp. served as lead agent for a $6 million credit facility for Respicardia Inc., an early stage medical device company. The money will be used for working capital and to complete a pilot study of the company’s sleep apnea treatment. Respicardia is backed by Three Arch Partners, Versant Ventures, Polaris Ventures Partners, Accuitive […]
If there’s a prize for market timing, Sequoia Capital ought to be a contender. The venture firm has managed an impressive spree of IPO and M&A exits over the past few quarters.
So many experts are confounded by the stellar performance of LinkedIn's stock since its IPO. They're missing what the company is really doing right.
In the past year, the storied VC firm has realized 18 exits, including Palo Alto Networks, Instagram and Jive Software
In 2011, the pension fund’s VC commitments added up to almost $210M
Jazz Pharmaceuticals’ acquisition of VC-backed Eusa Pharma for $680M was the largest M&A deal in the sector in the past year
Terry Moore’s fund focuses on tech and med tech companies in the area, but the investor says he is willing to expand
One day after Genomatica pulled its own IPO (and opted for some more time on the shelf and a new round), sources tell Reuters that LegalZoom is holding off on going public, citing market conditions. Was Friday the right day for that call?